MX2016000385A - Uso de un antagonista vegf en el tratamiento de la retinopatia de la prematuridad. - Google Patents

Uso de un antagonista vegf en el tratamiento de la retinopatia de la prematuridad.

Info

Publication number
MX2016000385A
MX2016000385A MX2016000385A MX2016000385A MX2016000385A MX 2016000385 A MX2016000385 A MX 2016000385A MX 2016000385 A MX2016000385 A MX 2016000385A MX 2016000385 A MX2016000385 A MX 2016000385A MX 2016000385 A MX2016000385 A MX 2016000385A
Authority
MX
Mexico
Prior art keywords
vegf antagonist
prematurity
infant
antagonist
treating retinopathy
Prior art date
Application number
MX2016000385A
Other languages
English (en)
Spanish (es)
Inventor
Sergey Aksenov
Gabriela Burian
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2016000385A publication Critical patent/MX2016000385A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F9/00821—Methods or devices for eye surgery using laser for coagulation
    • A61F9/00823—Laser features or special beam parameters therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Otolaryngology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Endocrinology (AREA)
MX2016000385A 2013-07-11 2014-07-10 Uso de un antagonista vegf en el tratamiento de la retinopatia de la prematuridad. MX2016000385A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361845073P 2013-07-11 2013-07-11
PCT/IB2014/063003 WO2015004626A2 (en) 2013-07-11 2014-07-10 Use of a vegf antagonist in treating retinopathy of prematurity

Publications (1)

Publication Number Publication Date
MX2016000385A true MX2016000385A (es) 2016-04-29

Family

ID=51211284

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000385A MX2016000385A (es) 2013-07-11 2014-07-10 Uso de un antagonista vegf en el tratamiento de la retinopatia de la prematuridad.

Country Status (14)

Country Link
US (1) US20160159893A1 (https=)
EP (1) EP3019527A2 (https=)
JP (1) JP2016523956A (https=)
KR (1) KR20160030504A (https=)
CN (1) CN105377890A (https=)
AR (1) AR096893A1 (https=)
AU (3) AU2014288847A1 (https=)
BR (1) BR112016000282A2 (https=)
CA (1) CA2917813A1 (https=)
HK (1) HK1221231A1 (https=)
MX (1) MX2016000385A (https=)
RU (1) RU2676303C2 (https=)
TW (1) TW201536317A (https=)
WO (1) WO2015004626A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
MY160399A (en) 2009-07-06 2017-03-15 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint, Inc. Methods for treating Vascular Leak Syndrome and cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
ES2981607T3 (es) 2015-09-23 2024-10-09 Eyepoint Pharmaceuticals Inc Activadores de Tie-2 para uso en el tratamiento de la presión intraocular
EP3397271B1 (en) 2015-12-30 2021-11-03 Marshall University Research Corporation Compositions and methods for treating retinopathy
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
AU2017299581B2 (en) 2016-07-20 2024-05-23 EyePoint, Inc. Humanized monoclonal antibodies that target ve-ptp (hptp-β)
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
EP3962482A4 (en) 2019-04-29 2023-01-11 EyePoint Pharmaceuticals, Inc. TIE 2 ACTIVATORS FACING THE SCHLEMM CHANNEL
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022097A1 (en) * 2002-09-05 2004-03-18 Medimmune, Inc. Methods of preventing or treating cell malignancies by administering cd2 antagonists
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
NZ592039A (en) * 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
EP3479844B1 (en) * 2005-04-15 2023-11-22 MacroGenics, Inc. Covalent diabodies and uses thereof
WO2007038453A2 (en) * 2005-09-26 2007-04-05 Advanced Ocular Systems Limited Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
EP2217329B1 (en) * 2007-11-07 2018-01-10 Anthrogenesis Corporation Use of umbilical cord blood in the treatment of premature birth complications
WO2010045506A2 (en) * 2008-10-16 2010-04-22 Kathleen Cogan Farinas Sustained drug delivery system
EP3785735A1 (en) 2008-11-03 2021-03-03 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
EP3028707A1 (en) * 2009-05-01 2016-06-08 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
RU2469734C2 (ru) * 2010-09-02 2012-12-20 Григорий Владимирович Пантелеев Лечебное средство для лечения расстройств аккомодаций "stiak"
US20140249191A1 (en) * 2011-10-20 2014-09-04 Avienne Pharmaceuticals Gmbh Compositions for Controlling Vascularization in Ophthalmological and Dermatological Diseases
KR102083700B1 (ko) * 2012-08-21 2020-03-02 옵코 파마슈티칼스, 엘엘씨 리포좀 제제

Also Published As

Publication number Publication date
AU2014288847A1 (en) 2016-01-28
WO2015004626A3 (en) 2015-05-28
TW201536317A (zh) 2015-10-01
JP2016523956A (ja) 2016-08-12
RU2016104398A3 (https=) 2018-05-31
CA2917813A1 (en) 2015-01-15
KR20160030504A (ko) 2016-03-18
BR112016000282A2 (pt) 2017-12-12
HK1221231A1 (zh) 2017-05-26
EP3019527A2 (en) 2016-05-18
WO2015004626A2 (en) 2015-01-15
AU2017204326A1 (en) 2017-07-13
RU2016104398A (ru) 2017-08-16
US20160159893A1 (en) 2016-06-09
AR096893A1 (es) 2016-02-03
CN105377890A (zh) 2016-03-02
RU2676303C2 (ru) 2018-12-27
AU2019206000A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
MX2016000385A (es) Uso de un antagonista vegf en el tratamiento de la retinopatia de la prematuridad.
MX2016000384A (es) Uso de un antagonista de vegf en el tratamiento de trastornos coriorretinianos neovasculares y de permeabilidad en pacientes pediatricos.
Okosun et al. A co-infection model of malaria and cholera diseases with optimal control
Evans et al. Are parenting interventions effective in improving the relationship between mothers and their preterm infants?
PH12018501325A1 (en) Compositions comprising human milk oligosaccharides for use in infants or young children to prevent or treat a health disorder by increasing glp-1 secretion
MX2016000364A (es) Metodos para tratar o prevenir afecciones oftalmologicas.
BR112018069789A2 (pt) medicamento obtido pela combinação do agonista de fxr e arb
PH12019500177A1 (en) Treatment and prevention of sleep disorders
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
WO2014184576A3 (en) Delivery of a therapeutic agent to the cerebral cortex by administering a viral vector by convection enhanced diffusion into the white matter of the brain
MX2018003028A (es) Reduccion de los niveles o de la actividad de los linfocitos t reguladores sistemicos para el tratamiento de enfermedades y lesiones del sistema nervioso central (snc).
SG10201903112WA (en) Treatment of cancer using coenzyme q10 combination therapies
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
MX2017004658A (es) Sulfatos de colesterol oxigenado para terapia contra trastornos provocados por al menos uno de actividad atenuada de leptina y un trastorno de almacenamiento lipidico.
PH12017500098A1 (en) Suspension compositions of cyclosporin a for subconjunctival and periocular injection
Fareed et al. Psychoimmunomodulatory activity of Salvadora persica L.(Miswak) extract on stress model in rats
MX2019013207A (es) Metodos y composiciones para tratar la endometriosis y sintomas asociados a la endometriosis.
Committee on Child Health Financing Guiding principles for managed care arrangements for the health care of newborns, infants, children, adolescents, and young adults
Pastore et al. Procedural sedation for intra-articular corticosteroid injections in juvenile idiopathic arthritis (JIA) should be a standard of care
AR102494A1 (es) Métodos para tratar enfermedades oculares
Van Der Meer Hyperammonaemic encephalopathy in a child: case report
Kathirvel Thrombocytopenia: case report
王扬 How A Dog’s 9 Babies Came To Be Called
Pratini Baclofen/lorazepam
Margetic Bilateral leg oedema: case report